USPTO serial 97243682
HIPRA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 9, 2025
- Examiner
- MAGIT, JACOB FLEMING
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HIPRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
LEIGH ANN LINDQUIST
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC2000 PENNSYLVANIA AVENUE NW, SUITE 9000WASHINGTON, DC 20006United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, namely, biological vaccines for human and veterinary use; biological preparations for medical and veterinary use, namely, veterinary vaccines; veterinary preparations for the treatment of intestinal bacteria; anti- infective products for veterinary use; insecticidal washing products for veterinary use; veterinary products and substances, namely, vaccines for prevention of animal illness; biological reagents for veterinary use; diagnostic reagents for veterinary use; reagents for clinical analyses for veterinary purposes; reagents for microbiological analyses for veterinary purposes; reagents for chemical analyses for veterinary purposes; reagents for veterinary diagnosis; reagents for diagnostic tests for veterinary purposes; reagents for use with analyzers for veterinary purposes; reagents for use in analyses for veterinary use, reagents for in-vitro laboratory use for veterinary purposes; reagents for use in analysis for veterinary use, reagents for in-vitro laboratory use for veterinary purposes; chemical reagents for medical or veterinary purposes; chemical reagents for veterinary use; reagents and media for medical and veterinary diagnostic purposes; nucleic acid sequences for medical and veterinary use; dietary supplements for veterinary use; veterinary substances and preparations, namely, vaccines for prevention of animal illness; oral vaccine preparations; vaccine preparations for human use; vaccines; influenza vaccines; vaccines against pneumococcal infections; vaccines for horses; vaccines for cattle; vaccines for infections in animal hooves; vaccines for human use; veterinary vaccines; viral vaccines | ACTIVE | Jul 23, 2024 |
| 042 | Scientific and technological services, as well as associated research and design services, namely, scientific research, analysis and testing in the field of pharmaceutical, veterinary, and sanitary products and material, surgical, medical, and veterinary apparatus, devices, and instruments; industrial analysis and research services in the field of pharmaceutical, veterinary, and sanitary products and material, surgical, medical, and veterinary apparatus, devices, and instruments, as well as of computer software related to the biomedical and pharmaceutical sector, and industrial design services; quality control services for others in the field of pharmaceutical, veterinary, and sanitary products and material, surgical, medical, and veterinary apparatus, devices and instruments; design and development of computer hardware and software; research and development of vaccines; veterinary laboratory services; services for assessing the effectiveness of veterinary medicines; design of laboratory animal housing systems; biotechnology research for determining the neuronal survival of molecules in animal models; research regarding farm animal breeding; genetic tests of laboratory animals for research; consultancy in pharmaceutical research; consultancy related to pharmacology; consultancy related to pharmacogenetics research; consultancy related to pharmaceutical research and development; development of pharmaceutical preparations and medicines; development of pharmaceutical products; clinical studies for pharmaceutical products; evaluation of pharmaceutical products; scientific and medical research information regarding pharmaceutical products and clinical trials; inspection of pharmaceutical products; scientific research in the field of pharmaceuticals; research in the field of pharmacogenetics; research regarding pharmaceutical products; research and development in the field of pharmaceuticals and biotechnology; pharmaceutical research and development; research and development for the pharmaceutical industry; conducting clinical trials for pharmaceutical products; conducting early evaluations in relation to new pharmaceutical products; pharmaceutical drug development services; drug discovery services; pharmaceutical product efficacy assessment services; medical and pharmacological research services; pharmaceutical research and development services; information technology services for the pharmaceutical and health-care industries, namely, information technology consulting services; provision of information regarding results of clinical trials relating to pharmaceutical products; electronic storage of medical records; design and development of medical diagnostic apparatus; scientific research for medical purposes; medical laboratories; programming for computers in the medical field; information and data services regarding medical and veterinary research and development; services of a medical laboratory; non-medical ultrasound imaging services; provision of scientific information regarding medical disorders and their treatment; research and development of vaccines and medicines; biological research and analysis; development of computer software in the pharmaceutical, medical, veterinary, sanitary and diagnostic field; clinical research in the field of veterinary preparations, biotherapeutic medicines, and antibodies; blood testing services for scientific research; scientific analysis services relating to the assessment of bacteria content in liquids | ACTIVE | Jul 23, 2024 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LABORATORIOS HIPRA, S.A.
- Other trademarks owned by LABORATORIOS HIPRA, S.A.
- Other trademarks owned by LABORATORIOS HIPRA, S.A.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named HIPRA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 9, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 9, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 19, 2025 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 19, 2025 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Oct 3, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 18, 2025 | IUAF | USE AMENDMENT FILED | — |
| Jun 18, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 19, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 19, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 20, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 20, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 20, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 19, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 18, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 18, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 18, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 18, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 18, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 6, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 6, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 12, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 12, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 12, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 24, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 23, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 23, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 23, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 23, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 23, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 24, 2022 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Feb 24, 2022 | ALIE | ASSIGNED TO LIE | — |
| Feb 18, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 1, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 1, 2022 | NWAP | NEW APPLICATION ENTERED | — |